Market Exclusive

Analyst Activity – Royal Bank Of Canada Lowers Its Price Target On Eagle Pharmaceuticals (NASDAQ:EGRX) to $81.00

Analyst Ratings For Eagle Pharmaceuticals (NASDAQ:EGRX)

Today, Royal Bank Of Canada lowered its price target on Eagle Pharmaceuticals (NASDAQ:EGRX) to $81.00 per share.

There are 1 sell rating, 3 buy ratings on the stock.

The current consensus rating on Eagle Pharmaceuticals (NASDAQ:EGRX) is Buy (Score: 2.50) with a consensus target price of $84.00 per share, a potential 57.39% upside.

Some recent analyst ratings include


Recent Trading Activity for Eagle Pharmaceuticals (NASDAQ:EGRX)
Shares of Eagle Pharmaceuticals closed the previous trading session at 53.37 down -16.67 -23.80% with 1,862,111 shares trading hands.

Exit mobile version